Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Hims & Hers’

Hims & Hers Stock: Buy the Dip or Wait It Out?

Hims & Hers stock is giving up some gains after announcing the acquisition of Zava, a European digital healthcare platform.

MarketBeat

IBD 50's Hims & Hers Erases Its 19% Acquisition-Tied Sprint

Hims stock shot higher and then fell Tuesday after the telehealth platform announced the pending acquisition of ZAVA, a European digital health platform.

Investors Business Daily

Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?

The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers Stock Rises on Fundamentals and Squeeze Potential

Hims & Hers stock is now giving investors another reason to consider it a buy for the coming months, as the latest quarterly earnings show momentum.

MarketBeat

Leading Weight-Loss Stock, Hims & Hers, Shrugs Off Outlook Worries And Spikes 18%

Hims stock reversed higher Tuesday after the telehealth platform issued a lackluster outlook for the current three-month period.

Investors Business Daily

Hims & Hers Names New COO. Stock Rallies.

Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer.

Investors Business Daily

Hims & Hers Stock Soars on Novo Nordisk Collaboration

Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

You might soon be able to get Wegovy from an online shop — here is where you need to visit

The move comes as Danish drugmaker Novo Nordisk has acted to slash the popular weight loss drug’s price

The Independent UK

Is Hims & Hers Stock a Buy, Sell, or Hold on Wegovy Telehealth News?

Hims & Hers stock rallies after announcing a partnership with Novo Nordisk. Analyst says there’s potential for further upside in HIMS shares.

Barchart

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

Investors Business Daily

Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.

Investors Business Daily

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

MarketBeat

Missed the Hims & Hers Rally? Clover Health Could Be Next

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Rise As Nvidia Partner Super Micro Soars; Tesla, Hims Lead Growth Woes

Futures rose as Nvidia partner Super Micro and Axon soared. Tesla and Hims dived Tuesday as growth stocks continue to struggle.

Barchart

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

Investors Business Daily

Dow Jones Futures Rise: Trump Tariffs 'Going Forward;' Nvidia, Palantir Sell Off; Hims Plunges Late

Dow Jones Futures: President Trump's tariffs on Canada and Mexico are "going forward." Nvidia and Palantir tumbled Monday.

Investors Business Daily

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Hims & Hers Earnings Could Be a Game Changer—What to Do Now

After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.

MarketBeat

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

Investors Business Daily

Hims & Hers Option Trade Offers $410 Return Or 17% Discount

The goal is to either have the put expire worthless and keep the premium, or be assigned and acquire the stock below the current price.

MarketBeat

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

Fortune

Ozempic, Wegovy maker claps back at Hims & Hers Super Bowl ad: ‘Check before you inject’

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

LiveScience

Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

Fortune

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.